Trial reportJournal of thrombosis and haemostasis : JTH2021
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban.
Trial report in Journal of thrombosis and haemostasis : JTH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis.World journal of clinical oncology · 2024Trial
- Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban.Journal of thrombosis and haemostasis : JTH · 2021Trial
- Pulmonary origin and risk assessment of cancer-associated thrombosis.Thrombosis journal · 2026Review
- Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding.Haematologica · 2025Article
- Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Observational
- Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer.Research and practice in thrombosis and haemostasis · 2025Article
- Advances in gastrointestinal vascular bleeding disorders: Successful sirolimus treatment in colonic angioectasia.World journal of gastroenterology · 2025Review
- Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review.Acta haematologica · 2025Review
- Analysis of influencing factors and construction of predictive model for major gastrointestinal bleeding after receiving VTE prophylactic anticoagulants in non-tumor patients.Frontiers in medicine · 2025Article
- Non-Invasive Cancer Detection Using Blood Test and Predictive Modeling Approach.Advances and applications in bioinformatics and chemistry : AABC · 2024Article
- Challenging issues in the management of cancer-associated venous thromboembolism.Blood research · 2022Review
- Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study.TH open : companion journal to thrombosis and haemostasis · 2022Article
- A Review of the Past, Present and Future of Cancer-associated Thrombosis Management.Heart international · 2022Review
- Nomogram for preoperative estimation of histologic grade in gastrointestinal neuroendocrine tumors.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 5 countries.
Funding
Abstract
backgroundIn the Hokusai VTE Cancer study, the risk of major bleeding was 2.9% higher in the edoxaban group compared with the dalteparin group, mainly due to more gastrointestinal bleedings in patients with gastrointestinal cancer. The identification of risk factors for gastrointestinal bleeding may help to guide the use of DOACs in these patients.
objectivesTo evaluate risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer receiving edoxaban. PATIENTS/
methodsIn this nested case-control study in patients with gastrointestinal cancer randomized to edoxaban in the Hokusai VTE Cancer study, cases (patients with clinically relevant gastrointestinal bleeding during treatment) were randomly matched to three controls (patients who had no gastrointestinal bleeding). Data for the 4-week period prior to bleeding were retrospectively collected. Odds ratios (ORs) were calculated in a crude conditional logistic regression model and a multivariable model adjusted for age, sex, and cancer type.
resultsTwenty-four cases and 64 matched controls were included. In the multivariable analysis, advanced cancer, defined as regionally advanced or metastatic cancer (OR 3.6, 95% CI 1.01-12.6) and low hemoglobin levels (OR 4.8, 95% CI 1.5-16.0) were significantly associated with bleeding. There was no significant difference in patients with resected tumors (OR 0.4, 95% CI 0.1-1.4), or in patients on chemotherapy (OR 1.3, 95% CI 0.5-3.5).
conclusionAdvanced cancer and low hemoglobin levels were associated with an increased risk of gastrointestinal bleeding in patients with gastrointestinal cancer receiving edoxaban. We were unable to identify other risk factors, mainly due to limited statistical power.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.